MCID: THL010
MIFTS: 39

Thalassemia Minor malady

Categories: Genetic diseases, Blood diseases

Aliases & Classifications for Thalassemia Minor

Aliases & Descriptions for Thalassemia Minor:

Name: Thalassemia Minor 24 69
Beta Thalassemia, Heterozygous 69
Heterozygous Beta-Thalassemia 24
Beta Thalassemia Heterozygous 52
Beta-Thalassemia Minor 24

Classifications:



Summaries for Thalassemia Minor

MalaCards based summary : Thalassemia Minor, also known as beta thalassemia, heterozygous, is related to thalassemia, hispanic gamma-delta-beta and nephropathy with pretibial epidermolysis bullosa and deafness. An important gene associated with Thalassemia Minor is HBA2 (Hemoglobin Subunit Alpha 2), and among its related pathways/superpathways are Malaria and African trypanosomiasis. The drugs Iron and Deferoxamine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and endothelial, and related phenotype is integument.

Related Diseases for Thalassemia Minor

Diseases related to Thalassemia Minor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Related Disease Score Top Affiliating Genes
1 thalassemia, hispanic gamma-delta-beta 11.8
2 nephropathy with pretibial epidermolysis bullosa and deafness 10.9
3 thrombocytopenia with beta-thalassemia, x-linked 10.9
4 thalassemia 10.7
5 michelin tire baby syndrome 10.2 HBA2 HBB
6 surfactant metabolism dysfunction, pulmonary, 3 10.2 HBA2 HBB
7 cardiomyopathy, dilated, 1w 10.2 HBA2 HBB
8 deficiency anemia 10.2
9 iron deficiency anemia 10.2
10 heparane sulfamidase deficiency 10.2 B2M HBB
11 sepsis in premature infants 10.2 HBB KLF1
12 pyloric stenosis, infantile hypertrophic, 4 10.2 EPO GATA1
13 isolated atp synthase deficiency 10.2 HBB KLF1
14 gaba-transaminase deficiency 10.1 HBA2 HBB
15 insensitivity to pain, congenital, with anhidrosis 10.1 GATA1 KLF1
16 renal tubular acidosis, distal, ar 10.1 GATA1 KLF1
17 tmem231-related joubert syndrome 10.1 HBA2 HBB
18 breast metaplastic carcinoma 10.1 B2M EPO
19 episcleritis periodica fugax 10.1 EPO HBB
20 brachydactyly type a1d 10.0 GATA1 HBB KLF1
21 tmem216-related meckel syndrome 10.0 EPO HBA2 HBB
22 endometriosis of uterus 10.0 HBB UGT1A1
23 brucella canis brucellosis 10.0 HBA2 HBB
24 adenosine triphosphate, elevated, of erythrocytes 10.0 EPO GATA1 HBA2
25 hepatitis b 10.0 EPO HBA2 HBB
26 borderline leprosy 10.0 HBB UGT1A1
27 heinz body anemia 10.0 HBA2 HBB UGT1A1
28 disseminated intravascular coagulation 10.0 EPO HBA2 KLF1
29 arthritis 9.9
30 drug-induced hepatitis 9.9 EPO GATA1 KLF1
31 cat-scratch disease 9.9 EPO HBA2
32 acute liver failure 9.9 EPO GATA1 HBB KLF1
33 hemochromatosis 9.9
34 hepatitis 9.9
35 liver disease 9.9
36 meningeal melanocytoma 9.8 EPO HBA2 HBB KLF1
37 neuronal ceroid-lipofuscinoses 9.8 EPO HBB PON1
38 tk2-related mitochondrial dna depletion syndrome, myopathic form 9.8 EPO HBA2 HBB UGT1A1
39 fetal hemoglobin quantitative trait locus 1 9.8 EPO HBA2 HBB UGT1A1
40 vagus nerve neoplasm 9.8 GATA1 HBB KLF1 UGT1A1
41 retinitis 9.8
42 bronchitis 9.8
43 thalassemia major 9.8
44 plastic bronchitis 9.8
45 hemoglobinopathy 9.8
46 purpura 9.6
47 hypersplenism 9.6
48 thyroiditis 9.6
49 retinitis pigmentosa 9.6
50 diabetes insipidus 9.6

Graphical network of the top 20 diseases related to Thalassemia Minor:



Diseases related to Thalassemia Minor

Symptoms & Phenotypes for Thalassemia Minor

MGI Mouse Phenotypes related to Thalassemia Minor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.02 B2M CD151 EPO GATA1 KLF1

Drugs & Therapeutics for Thalassemia Minor

Drugs for Thalassemia Minor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1 7439-89-6 23925
2
Deferoxamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 70-51-9 2973
3
Ribavirin Approved Phase 4 36791-04-5 37542
4
Deferiprone Approved Phase 4,Phase 2,Phase 3,Phase 1 30652-11-0 2972
5
Deferasirox Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 201530-41-8 5493381
6
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
7
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
8
Zinc Approved Phase 4 7440-66-6 32051 23994
9
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
10
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
11
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
13 Zinc sulfate Approved Phase 4 7733-02-0
14
Methotrexate Approved Phase 4,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
15
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
16
Metformin Approved Phase 4 657-24-9 14219 4091
17
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
18
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
19
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21 vitamin d Phase 4
22 interferons Phase 4
23 Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
24 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
25 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
26 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
27 Vaccines Phase 4
28 Ergocalciferols Phase 4
29 Vitamins Phase 4,Phase 2,Phase 3
30 Anti-Infective Agents Phase 4,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
32 Interferon-alpha Phase 4
33 Iron Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
35 Antimetabolites Phase 4,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 1
37 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
38 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3
39 Antiviral Agents Phase 4,Phase 2,Phase 1
40 Calcium, Dietary Phase 4,Phase 2,Phase 3
41 Dermatologic Agents Phase 4,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
43 Antifungal Agents Phase 4,Phase 2,Phase 1
44 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 1
45 Astringents Phase 4
46 Antirheumatic Agents Phase 4,Phase 2,Phase 1
47 Calcineurin Inhibitors Phase 4,Phase 2,Phase 1
48 Folic Acid Antagonists Phase 4
49 Vitamin B Complex Phase 4
50 Immunoglobulins Phase 4

Interventional clinical trials:

(show top 50) (show all 177)
id Name Status NCT ID Phase
1 Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major Unknown status NCT00103753 Phase 4
2 B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals Unknown status NCT01846923 Phase 4
3 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4
4 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4
5 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4
6 Efficacy Study of the Use of Sequential DFP-DFO Versus DFP Completed NCT00733811 Phase 4
7 Post Hematopoietic Stem Cell Transplantation Completed NCT01610297 Phase 4
8 Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia Completed NCT03095326 Phase 4
9 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Completed NCT00171301 Phase 4
10 Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major Completed NCT00800761 Phase 4
11 Zinc Supplementation on Cellular Immunity in Thalassemia Major Completed NCT03117192 Phase 4
12 Efficacy Study in Removing Excess Iron From the Heart Completed NCT00105495 Phase 4
13 Pilot Study for Patients With Poor Response to Deferasirox Completed NCT00749515 Phase 4
14 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Recruiting NCT02342145 Phase 4
15 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4
16 the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children Active, not recruiting NCT02674607 Phase 4
17 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Not yet recruiting NCT02984475 Phase 4
18 An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old Withdrawn NCT01724138 Phase 4
19 Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients Unknown status NCT01016093 Phase 2, Phase 3
20 An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Unknown status NCT02173951 Phase 2, Phase 3
21 Therapeutic Effects of Silymarin in Patients With B-thalassemia Major Unknown status NCT00999349 Phase 2, Phase 3
22 Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin. Unknown status NCT01624038 Phase 2, Phase 3
23 Role of Vitamin C to Augment Iron Chelation With DFP or DFX Unknown status NCT02083575 Phase 2, Phase 3
24 Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload Unknown status NCT01511848 Phase 2, Phase 3
25 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
26 Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Completed NCT01125254 Phase 2, Phase 3
27 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload Completed NCT00171210 Phase 3
28 A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis Completed NCT00171171 Phase 3
29 Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions Completed NCT00061750 Phase 3
30 Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Completed NCT01395199 Phase 3
31 Effect of Metoprolol on Thalassemia Cardiomyopathy Completed NCT01863173 Phase 2, Phase 3
32 Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease Completed NCT00943748 Phase 2, Phase 3
33 Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study Completed NCT01033747 Phase 2, Phase 3
34 A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia Recruiting NCT02906202 Phase 3
35 Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion Active, not recruiting NCT01740531 Phase 3
36 An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia Active, not recruiting NCT02604433 Phase 3
37 Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients Active, not recruiting NCT01825512 Phase 3
38 Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis Not yet recruiting NCT03040765 Phase 3
39 Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both Unknown status NCT00738413 Phase 1, Phase 2
40 Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia Unknown status NCT01005576 Phase 2
41 Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon Completed NCT01642758 Phase 2
42 Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment Completed NCT00447694 Phase 2
43 Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia Completed NCT00809042 Phase 2
44 Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia Completed NCT00069862 Phase 1, Phase 2
45 Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand Completed NCT01609595 Phase 2
46 Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia Completed NCT01749540 Phase 2
47 Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia Completed NCT00790127 Phase 1, Phase 2
48 Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia) Completed NCT00001958 Phase 2
49 Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia Completed NCT00661726 Phase 2
50 A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. Completed NCT00390858 Phase 2

Search NIH Clinical Center for Thalassemia Minor

Genetic Tests for Thalassemia Minor

Genetic tests related to Thalassemia Minor:

id Genetic test Affiliating Genes
1 Thalassemia Minor 24

Anatomical Context for Thalassemia Minor

MalaCards organs/tissues related to Thalassemia Minor:

39
Liver, Testes, Endothelial, Thyroid, Bone, Kidney, Whole Blood

Publications for Thalassemia Minor

Articles related to Thalassemia Minor:

(show top 50) (show all 159)
id Title Authors Year
1
Assessing posterior ocular structures in I^-thalassemia minor. ( 28054212 )
2017
2
Presacral and intrathoracic extramedullary hematopoiesis in a patient with I^ thalassemia minor. ( 27148799 )
2016
3
A Number of Cases in Iran Presenting with Coinheritance of Hb H Disease and I^-Thalassemia Minor. ( 27535574 )
2016
4
Evaluation of Platelet and Red Blood Cell Parameters with Proposal of Modified Score as Discriminating Guide for Iron Deficiency Anemia and I^-Thalassemia Minor. ( 27437228 )
2016
5
Severe mechanical hemolysis in a patient with thalassemia minor who had undergone inappropriate splenectomy. ( 27206816 )
2016
6
Retinal nerve fiber layer thickness and retinal vessel calibers in children with thalassemia minor. ( 27540484 )
2016
7
Serum Lipids in Turkish Patients with I^-Thalassemia Major and I^-Thalassemia Minor. ( 26376943 )
2015
8
Reliability of Different RBC Indices and Formulas in Discriminating between I^-Thalassemia Minor and other Microcytic Hypochromic Cases. ( 25745549 )
2015
9
A new KrA1ppel-like factor 1 mutation (c.947Ga88>a88A or p.C316Y) in humans causes I^-thalassemia minor. ( 25690802 )
2015
10
Prevalence of iron deficiency in thalassemia minor. ( 24554833 )
2014
11
Plastic bronchitis in beta thalassemia minor. ( 24669100 )
2014
12
Cut off Determination of Discrimination Indices in Differential Diagnosis between Iron Deficiency Anemia and I^- Thalassemia Minor. ( 24800036 )
2014
13
Oxidation status of I^-thalassemia minor and Hb H disease, and its association with glycerol lysis time (GLT50). ( 24611654 )
2014
14
Serum Bcl-2 Levels in Patients with I^-Thalassemia Minor: A Pilot Study. ( 25541652 )
2014
15
Coexistence of Two I^-Globin Gene Deletions in a Chinese Girl with I^-Thalassemia Minor. ( 24200214 )
2014
16
Use of serum iron status and hemoglobin A2 levels for discrimination between iron deficiency and thalassemia minor. ( 23327659 )
2013
17
Determining and surveying the role of carnitine and folic acid to decrease fatigue in I^-thalassemia minor subjects. ( 23458634 )
2013
18
Identification of IVS-I (-1) (G > C) or Hb Monroe as a report on the beta-globin gene with a beta-thalassemia minor phenotype in south of Iran. ( 23981164 )
2013
19
Beta-thalassemia minor is associated with IgA nephropathy. ( 23479564 )
2013
20
Depression in subjects with beta-thalassemia minor. ( 23892926 )
2013
21
Comparison between I^-thalassemia minor and normal individuals using the Wechsler Adult Intelligence Scale. ( 23806085 )
2013
22
Nephrogenic diabetes insipidus with intracranial calcification in a child with thalassemia minor. ( 24053747 )
2013
23
Coronary Microvascular function, Peripheral Endothelial Function and Carotid IMT in beta-thalassemia minor. ( 23683324 )
2013
24
Pseudothrombocytosis due to microerythrocytosis: a case of beta thalassemia minor complicated with iron deficiency anemia. ( 23485560 )
2013
25
Plastic bronchitis in beta thalassemia minor. ( 24049256 )
2013
26
Differential diagnostics of thalassemia minor by artificial neural networks model. ( 24218131 )
2013
27
Combined iron deficiency and thalassemia minor. ( 23355213 )
2013
28
Premarital Screening of Beta Thalassemia Minor in north-east of Iran. ( 24575266 )
2013
29
Genotoxicity assessment in patients with thalassemia minor. ( 22414564 )
2012
30
Prevalance of iron deficiency in thalassemia minor: a study from tertiary hospital. ( 23449336 )
2012
31
Kidney function tests in children with beta-thalassemia minor in Zahedan, southeast of Iran. ( 21525581 )
2011
32
Evidence for a proatherogenic biochemical phenotype in beta thalassemia minor and intermedia. ( 21576933 )
2011
33
Ambulatory blood pressure profile in hypertensive patients with I^-thalassemia minor. ( 21124332 )
2011
34
Reconstruction of the thumb with a modified wrap-around flap in a patient suffering from I^-thalassemia minor. ( 22072476 )
2011
35
Proposal of a score combining red blood cell indices for early differentiation of beta-thalassemia minor from iron deficiency anemia. ( 21418745 )
2011
36
Markedly low hemoglobin A1c in a patient with an unusual presentation of beta-thalassemia minor. ( 19703808 )
2010
37
Distribution of I^-Globin Gene Mutations in Thalassemia Minor Population of Kerman Province, Iran. ( 23113009 )
2010
38
Identification of a new mutation on the beta-globin gene: codons 8/9 (+AGAA); GAG.AAG.TCT(Glu-Lys-Ser)>GAG. AAAGAAG, in a patient from the north of France with a phenotype of beta-thalassemia minor. ( 20642337 )
2010
39
A new index for discrimination between iron deficiency anemia and beta-thalassemia minor: results in 284 patients. ( 19579993 )
2009
40
Prevalence of hepatosplenomegaly in beta thalassemia minor subjects in Iran. ( 18029131 )
2009
41
Acute splenic infarct in beta-thalassemia minor: a novel combination of heterozygous beta-globin mutations with latent phenotypes and the clinical implications. ( 19657842 )
2009
42
Treatment with hydroxyurea in a patient compound heterozygote for a high oxygen affinity hemoglobin and beta-thalassemia minor. ( 19787797 )
2009
43
Red cell distribution width in iron deficiency anemia and beta-thalassemia minor. ( 18697290 )
2008
44
{beta}-thalassemia major evolution from {beta}-thalassemia minor is associated with paternal uniparental isodisomy of chromosome 11p15. ( 18413893 )
2008
45
Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor. ( 19043680 )
2008
46
Inadequate awareness of the role of erythrocytic parameters in the detection of beta-thalassemia minor. ( 18296817 )
2008
47
An increased prevalence of fibromyalgia in iron deficiency anemia and thalassemia minor and associated factors. ( 18404239 )
2008
48
Iron deficiency anemia, beta-thalassemia minor, and anemia of chronic disease: a morphologic reappraisal. ( 18285271 )
2008
49
Hb Lepore-Leiden: a new delta/beta rearrangement associated with a beta-thalassemia minor phenotype. ( 18932069 )
2008
50
Evaluation of iron status by serum ferritin level in Iranian carriers of beta thalassemia minor. ( 19326343 )
2008

Variations for Thalassemia Minor

Expression for Thalassemia Minor

Search GEO for disease gene expression data for Thalassemia Minor.

Pathways for Thalassemia Minor

Pathways related to Thalassemia Minor according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.95 HBA2 HBB
2 10.7 HBA2 HBB
3
Show member pathways
10.5 HBA2 HBB
4 10.48 EPO GATA1 KLF1

GO Terms for Thalassemia Minor

Cellular components related to Thalassemia Minor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.72 B2M EPO HBA2 HBB PON1
2 blood microparticle GO:0072562 9.43 HBA2 HBB PON1
3 tertiary granule lumen GO:1904724 9.37 B2M HBB
4 endocytic vesicle lumen GO:0071682 9.16 HBA2 HBB
5 hemoglobin complex GO:0005833 8.96 HBA2 HBB
6 haptoglobin-hemoglobin complex GO:0031838 8.62 HBA2 HBB

Biological processes related to Thalassemia Minor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular oxidant detoxification GO:0098869 9.48 HBA2 HBB
2 protein heterooligomerization GO:0051291 9.46 HBA2 HBB
3 response to hydrogen peroxide GO:0042542 9.43 HBA2 HBB
4 bicarbonate transport GO:0015701 9.4 HBA2 HBB
5 positive regulation of cell death GO:0010942 9.37 HBA2 HBB
6 platelet aggregation GO:0070527 9.32 GATA1 HBB
7 acute-phase response GO:0006953 9.26 EPO UGT1A1
8 hydrogen peroxide catabolic process GO:0042744 9.16 HBA2 HBB
9 oxygen transport GO:0015671 8.96 HBA2 HBB
10 erythrocyte differentiation GO:0030218 8.8 EPO GATA1 KLF1

Molecular functions related to Thalassemia Minor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxygen binding GO:0019825 9.26 HBA2 HBB
2 peroxidase activity GO:0004601 9.16 HBA2 HBB
3 oxygen transporter activity GO:0005344 8.96 HBA2 HBB
4 haptoglobin binding GO:0031720 8.62 HBA2 HBB

Sources for Thalassemia Minor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....